# US 2009/0269740 A1 · Pancreatic Cancer Genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269740 A1
- Document ID: US20090269740A1
- Status: Published application
- Kind: A1
- Application number: 11/929,777
- Filed: 2007-10-30
- Published: 2009-10-29
- Earliest claimed: 1998-06-23
- Inventors: Giulia C. Kennedy
- Web page: https://patentgrep.com/patent/US20090269740A1

## CPC

- C07K 14/47: from mammals
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.

## Claims

### Claim 1

A method of diagnosing cancer in a patient comprising comparing the amount of a polypeptide in a patient sample and in a normal sample, wherein said polypeptide comprises the polypeptide encoded by SEQ ID NO: 12, or a naturally occurring variant of SEQ ID NO: 12, wherein said naturally occurring variant hybridizes to SEQ ID NO: 12 under conditions including a wash in 2×SCC, 0.1% SDS at 50° C. for 20 minutes; and wherein a patient sample containing less of said polypeptide than the normal sample is identified as cancerous.

### Claim 2

A method of diagnosing cancer in a patient comprising determining the amount of a polypeptide in a patient sample and in a normal sample, wherein said first polypeptide is encoded by a polynucleotide selected from the group consisting of SEQ ID NOS: 1, 3-4, 6-11, and 13-14; determining the amount of a second polypeptide in the patient sample and in the normal sample, wherein said second polypeptide is encoded by SEQ ID NO: 12; and comparing the determined amounts; wherein a patient sample which contains less of the second polypeptide than the normal sample and which contains substantially the same amount of the first polypeptide, as compared to the normal sample, is identified as cancerous.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the cancer is pancreatic cancer.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the patient sample and the normal sample comprise pancreatic cells.
